Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools

References

• Thai KM, Ecker GF. A binary QSAR model for classification of hERG potassium channel blockers. Bioorg Med Chem 2008;16:4107–19
   PubMed Web of Science ®Google Scholar
• Moorthy NSHN, Karthikeyan C, Trivedi P. Synthesis, cytotoxic evaluation and in silico pharmacokinetic prediction of some benzo[a]phenazine-5-sulfonic acid derivatives. Med Chem 2009;5:549–57
   Google Scholar
• Bugrim A, Nikolskaya T, Nikolsky Y. Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov Today 2004;9:127–35
   PubMed Web of Science ®Google Scholar
• Aronov AM. Predictive in silico modeling for hERG channel blockers. Drug Discov Today: Biosilico 2005;10:149–55
   Google Scholar
• Moorthy NSHN, Sousa SF, Ramos MJ, Fernandes PA. In silico based structural analysis of arylthiophene derivatives for FTase inhibitory activity, hERG and other toxic effects. J Biomol Screen 2011;16:1037–46
   PubMed Web of Science ®Google Scholar
• Durdagi S, Guo J, Lees-Miller JP, et al. Structure-guided topographic mapping and mutagenesis to elucidate binding sites for the human ether-a-go-go-related gene 1 potassium channel (KCNH2) activator NS1643. J Pharmacol Exp Ther 2012;342:441–52
   PubMed Web of Science ®Google Scholar
• Subbotina J, Yarov-Yarovoy V, Lees-Miller J, et al. Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane and molecular dynamics simulations. Proteins 2010;78:2922–34
   PubMed Web of Science ®Google Scholar
• Vandenberg JI, Perry MD, Perrin MJ, et al. hERG K+ channels: structure, function, and clinical significance. Physiol Rev 2012; 92:1393–478
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006;440:463–9
   PubMed Web of Science ®Google Scholar
• Su BH, Shen MY, Esposito EX, et al. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage. J Chem Inf Model 2010;50:1304–18
   PubMed Web of Science ®Google Scholar
• Moorthy NSHN, Ramos MJ, Fernandes PA. hERG binding feature analysis of structurally diverse compounds by QSAR and fragmental analysis. RSC Adv 2011;1:1126–36
   Web of Science ®Google Scholar
• Moorthy NSHN, Ramos MJ, Fernandes PA. Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds. SAR QSAR Environ Res 2012;23:521–36
   PubMed Web of Science ®Google Scholar
• Moorthy NSHN, Ramos MJ, Fernandes PA. Structural analysis of 2-piperidin-4-yl-actamide derivatives for hERG blocking and MCH R1 antagonistic activities. Curr Drug Discov Tech 2012;9:25–38
   Google Scholar
• Du L, Li M, You Q, Xia L. A novel structure-based virtual screening model for the hERG channel blockers. Biochem Biophy Res Comm 2007;355:889–94
   PubMed Web of Science ®Google Scholar
• Durdagi S, Duff HJ, Noskov SJ. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain. J Chem Inf Model 2011;51:463–74
   PubMed Web of Science ®Google Scholar
• Du-Cuny L, Chen L, Zhang S. A critical assessment of combined ligand- and structure-based approaches to hERG channel blocker modeling. J Chem Inf Model 2011;51:2948–60
   PubMed Web of Science ®Google Scholar
• Yoshida K, Niwa T. Quantitative structure–activity relationship studies on inhibition of hERG potassium channels. J Chem Inf Model 2006;46:1371–8
   PubMed Web of Science ®Google Scholar
• Beshore DC, Liverton NJ, McIntyre CJ, et al. Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett 2010;20:2493–6
   PubMed Web of Science ®Google Scholar
• Shen MY, Su BH, Esposito EX, et al. Comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets. Chem Res Toxicol 2011;24:934–49
   Google Scholar
• Lavalle SM, Finn P, Kavraki LE, Latombe JC. A randomized kinematics-based approach to pharmacophore-constrained conformational search and database screening. J Comput Chem 2000;21:731–47
   Google Scholar
• Moorthy NSHN, Ramos MJ, Fernandes PA. Pharmacophore based screening and QSAR analysis of structurally diverse compounds for lead selection and optimization against multiple targets. OpenTox InterAction Meeting on Innovation in Predictive Toxicology; 2011 Aug 10–12; Munich, Germany
   Google Scholar
• De Maesschalck R, Jouan-Rimbaud D, Massart DL. The Mahalanobis distance. Chemom Intell Lab Sys 2000;50:1–18
   Web of Science ®Google Scholar
• Moorthy NSHN, Sousa SF, Ramos MJ, Fernandes PA. Structural feature study of benzofuran derivatives as farnesyltransferase inhibitors. J Enz Inhibit Med Chem 2011;26:777–91
   PubMed Web of Science ®Google Scholar
• Jamieson C, Moir EM, Rankovic Z, Wishart G. Medicinal chemistry of hERG optimizations: highlights and Hang-ups. J Med Chem 2006;49:5029–46
   PubMed Web of Science ®Google Scholar
• Lin A. QuaSAR-descriptors. Montreal, Canada: Chemical Computing Group Inc.; 2002
   Google Scholar
• Golbraikh A, Tropsha A. Beware of Q2. J Mol Graphs Model 2002;20:269–76
   PubMed Web of Science ®Google Scholar
• Moorthy NSHN, Ramos MJ, Fernandes PA. Analysis of α-glucosidase inhibitory activity of chromenone derivatives by its molecular features: a computational study. Med Chem 2011;7:526–33
   PubMed Web of Science ®Google Scholar
• Choe H, Nah KH, Lee SN, et al. A novel hypothesis for the binding mode of hERG channel blockers. Biochem Biophy Res Comm 2004;344:72–8
   Google Scholar
• Moorthy NSHN, Ramos MJ, Fernandes PA. Structural analysis of α-glucosidase inhibitors by validated QSAR models using topological and hydrophobicity based descriptors. Chemom Intell Lab Sys 2011;109:101–12
   Web of Science ®Google Scholar
• Guha R, Van Drie JH. Structure-activity landscape index: identifying and quantifying activity cliffs. J Chem Inf Model 2008;48:646–58
   PubMed Web of Science ®Google Scholar
• Moorthy NSHN, Ramos MJ, Fernandes PA. Comparative structural analysis of α-glucosidase inhibitors against difference species: a computational study. Arch Pharm 2012;345:265–74
   Google Scholar
• Moorthy NSHN, Ramos MJ, Fernandes PA. Structural analysis of structurally diverse α-glucosidase inhibitors for active site feature analysis. J Enz Inhibit Med Chem 2012;27:649–57
   Google Scholar
• Cook RD. Influential observations in linear-regression. J Am Stat Assoc 1979;74:169–74
   Web of Science ®Google Scholar
• Cruciani C, Crivori P, Carrupt PA, Testa B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J Mol Struct (Theochem) 2000;503:17–30
   Web of Science ®Google Scholar
• Myokai T, Ryu S, Shimizu H, Oiki S. Topological mapping of the asymmetric drug binding to the human ether-a-go-go-related gene product (hERG) potassium channel by use of tandem dimmers. Mol Pharmacol 2008; 73:1643–51
   Google Scholar
• Moorthy NSHN, Ramos MJ, Fernandes PA. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design. Curr Drug Targets 2013;14:102–13
   Google Scholar
• Durdagi S, Subbotina J, Lees-Miller J, et al. Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs. Curr Med Chem 2010;17:3514–32
   PubMed Web of Science ®Google Scholar
• Perrin MJ, Kuchel PW, Campbell TJ, Vandenberg JI. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Mol Pharmacol 2008;74:1443–52
   PubMed Web of Science ®Google Scholar
• Durdagi S, Deshpande S, Duff HJ, Noskov SY. Modeling of open, closed, and open-inactivated states of the hERG1 channel: structural mechanisms of the state-dependent drug binding. J Chem Inf Model 2012;52: 2760–74
   PubMed Web of Science ®Google Scholar